Table 2.
Baseline characteristics of cases and controls
| Categorical: n (%) | P value1 | |||
|
Continuous: median (IQR) | ||||
| Total | Case (n = 13) | Controls (n = 29) | ||
| Demographics and clinical characteristics | ||||
| Age (yr) | 60 (56-65) | 64 (56-68) | 60 (57-64) | 0.97 |
| Gender, female | 14 (33) | 6 (46) | 8 (28) | 0.15 |
| Race, black | 4 (9) | 1 (7) | 3 (10) | 1.00 |
| Ethnicity, Hispanic | 9 (21) | 1 (7) | 8 (28) | 0.23 |
| Weight (lbs) | 163 (146-182) | 155 (122-168) | 170 (147-193) | 0.04 |
| BMI (kg/m2) | 26.4 (22.6-28.7) | 25.6 (21.6-27.8) | 26.7 (24.6-29.0) | 0.12 |
| Years since Transplant | 5.4 (2.1–8.8) | 4.98 (1.7-7.5) | 5.6 (2.7-8.8) | 0.52 |
| Comorbidities | ||||
| Hepatocellular Carcinoma | 16 (38) | 5 (38) | 11 (38) | 1.00 |
| Diabetes | 21 (50) | 6 (46) | 15 (52) | 1.00 |
| Hypertension | 27 (64) | 9 (69) | 18 (62) | 0.74 |
| Depression | 5 (12) | 1 (8) | 4 (14) | 1.00 |
| Liver disease severity | ||||
| Cirrhosis | 8 (19) | 3 (23) | 5 (17) | 0.69 |
| FIB-4 | 4.81 (3.00-7.02) | 6.57 (3.12-8.94) | 4.49 (2.78-6.71) | 0.24 |
| FIB-4, ≥ 3.25 | 28 (67) | 9 (69) | 19 (65) | 1.00 |
| Treatment naïve | 9 (21) | 3 (23) | 6 (21) | 1.00 |
| Treatment Regimen | ||||
| SOF/RBV | 38 (90) | 12 (92) | 26 (90) | 1.00 |
| SOF/PEG/RBV | 4 (10) | 1 (8) | 3 (10) | 1.00 |
| Genotype | ||||
| 1 | 31 (74) | 8 (62) | 23 (79) | 0.27 |
| 2 | 3 (7) | 2 (15) | 1 (3) | 0.22 |
| 3 | 5 (12) | 2 (15) | 3 (10) | 0.64 |
| 4 | 2 (5) | 1 (8) | 1 (3) | 0.53 |
| Labs | ||||
| Hemoglobin (g/dL) (Ref: 13.9-16.3 g/dL) | 12.7 (10.8-14.2) | 11.3 (9.6-12.4) | 12.9 (12.2-14.5) | 0.01 |
| Platelets (× 103/μL) (Ref: 150-450 × 103/μL) | 117 (82-148) | 113 (85-138) | 121 (81-150) | 0.21 |
| HCV viral load (log10) (IU/mL) (Ref: 15-108 IU/mL) | 6.53 (6.27-6.72) | 6.59 (6.07-6.70) | 6.53 (6.32-6.76) | 0.81 |
| Serum creatinine (mg/dL) (Ref: 0.70-1.40 mg/dL) | 1.44 (1.10-1.72) | 1.60 (1.33-1.86) | 1.23 (1.04-1.60) | 0.06 |
| eGFR (mL/min per 1.73 m2 Albumin, g/dL) (Ref: 3.5-4.9 g/dL) | 49 (41-67) | 42 (32-49) | 56 (44-70) | 0.01 |
| 3.8 (3.5-4.1) | 3.6 (2.9-3.9) | 3.8 (3.6-4.1) | 0.23 | |
| ALT (U/L) (Ref: 1-53 U/L) | 59 (39-82) | 43 (33-72) | 65 (42-89) | 0.15 |
| AST (U/L) (Ref: 1-50 U/L) | 62 (49-92) | 61 (53-77) | 64 (41-93) | 0.95 |
| INR | 1.0 (1.0-1.2) | 1.0 (0.9-1.3) | 1.0 (1.0-1.1) | 0.852 |
| Total bilirubin (mg/dL) (Ref: 0.1-1.2 mg/dL) | 0.7 (0.5-1.1) | 0.8 (0.6-2.2) | 0.7 (0.5-1.0) | 0.10 |
| Alpha fetoprotein (ng/mL) (Ref: 0.0-9.0 ng/mL) | 5.0 (3.1-9.2) | 5.0 (3.5-12.1) | 5.0 (3.0-8.2) | 0.40 |
1
Student t test unless noted otherwise;
2
Mann-Whitney. BMI: Body mass index; SOF: Sofosbuvir; RBV: Ribavirin; PEG: Pegylated interferon; eGFR: Estimated glomerular filtration rate; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; INR: International normalized ratio.